340 related articles for article (PubMed ID: 31323990)
21. Liquid Biopsy in Tumor Genetic Diagnosis.
Jung A; Kirchner T
Dtsch Arztebl Int; 2018 Mar; 115(10):169-174. PubMed ID: 29587961
[TBL] [Abstract][Full Text] [Related]
22. Critical issues in the clinical application of liquid biopsy in non-small cell lung cancer.
Manicone M; Poggiana C; Facchinetti A; Zamarchi R
J Thorac Dis; 2017 Oct; 9(Suppl 13):S1346-S1358. PubMed ID: 29184673
[TBL] [Abstract][Full Text] [Related]
23. Clinical feasibility of NGS liquid biopsy analysis in NSCLC patients.
Papadopoulou E; Tsoulos N; Tsantikidi K; Metaxa-Mariatou V; Stamou PE; Kladi-Skandali A; Kapeni E; Tsaousis G; Pentheroudakis G; Petrakis D; Lampropoulou DI; Aravantinos G; Varthalitis I; Kesisis G; Boukovinas I; Papakotoulas P; Katirtzoglou N; Athanasiadis E; Stavridi F; Christodoulou C; Koumarianou A; Eralp Y; Nasioulas G
PLoS One; 2019; 14(12):e0226853. PubMed ID: 31860648
[TBL] [Abstract][Full Text] [Related]
24. IQN path ASBL report from the first European cfDNA consensus meeting: expert opinion on the minimal requirements for clinical ctDNA testing.
Deans ZC; Butler R; Cheetham M; Dequeker EMC; Fairley JA; Fenizia F; Hall JA; Keppens C; Normanno N; Schuuring E; Patton SJ
Virchows Arch; 2019 Jun; 474(6):681-689. PubMed ID: 31028539
[TBL] [Abstract][Full Text] [Related]
25. Liquid biopsy in early stage lung cancer.
Pérez-Ramírez C; Cañadas-Garre M; Robles AI; Molina MÁ; Faus-Dáder MJ; Calleja-Hernández MÁ
Transl Lung Cancer Res; 2016 Oct; 5(5):517-524. PubMed ID: 27826533
[TBL] [Abstract][Full Text] [Related]
26. Liquid Biopsy in Non-Small Cell Lung Cancer: Highlights and Challenges.
Rijavec E; Coco S; Genova C; Rossi G; Longo L; Grossi F
Cancers (Basel); 2019 Dec; 12(1):. PubMed ID: 31861557
[TBL] [Abstract][Full Text] [Related]
27. The detection and significance of EGFR and BRAF in cell-free DNA of peripheral blood in NSCLC.
Yang Y; Shen X; Li R; Shen J; Zhang H; Yu L; Liu B; Wang L
Oncotarget; 2017 Jul; 8(30):49773-49782. PubMed ID: 28572536
[TBL] [Abstract][Full Text] [Related]
28. Liquid biopsy: A potential and promising diagnostic tool for advanced stage non-small cell lung cancer patients.
Doval DC; Deshpande R; Dhabhar B; Babu KG; Prabhash K; Chopra R; Sripada PV; Deshmukh C; Suryavanshi M
Indian J Cancer; 2017 Dec; 54(Supplement):S25-S30. PubMed ID: 29292705
[TBL] [Abstract][Full Text] [Related]
29. Extracellular Vesicles in Non-Small-Cell Lung Cancer: Functional Role and Involvement in Resistance to Targeted Treatment and Immunotherapy.
Pasini L; Ulivi P
Cancers (Basel); 2019 Dec; 12(1):. PubMed ID: 31877735
[TBL] [Abstract][Full Text] [Related]
30. Validation of Cell-Free DNA Collection Tubes for Determination of EGFR Mutation Status in Liquid Biopsy from NSCLC Patients.
Sesé M; Somoza R; Maestu I; Ureste MM; Sanchez A; Cordoba JF; Sansano I; Venturas G; Ramón Y Cajal S; Hernández-Losa J
Oncol Ther; 2019 Dec; 7(2):131-139. PubMed ID: 32699985
[TBL] [Abstract][Full Text] [Related]
31. Measuring tumor mutation burden in non-small cell lung cancer: tissue versus liquid biopsy.
Fenizia F; Pasquale R; Roma C; Bergantino F; Iannaccone A; Normanno N
Transl Lung Cancer Res; 2018 Dec; 7(6):668-677. PubMed ID: 30505711
[TBL] [Abstract][Full Text] [Related]
32. Unique genetic profiles from cerebrospinal fluid cell-free DNA in leptomeningeal metastases of EGFR-mutant non-small-cell lung cancer: a new medium of liquid biopsy.
Li YS; Jiang BY; Yang JJ; Zhang XC; Zhang Z; Ye JY; Zhong WZ; Tu HY; Chen HJ; Wang Z; Xu CR; Wang BC; Du HJ; Chuai S; Han-Zhang H; Su J; Zhou Q; Yang XN; Guo WB; Yan HH; Liu YH; Yan LX; Huang B; Zheng MM; Wu YL
Ann Oncol; 2018 Apr; 29(4):945-952. PubMed ID: 29346604
[TBL] [Abstract][Full Text] [Related]
33. The first liquid biopsy test approved. Is it a new era of mutation testing for non-small cell lung cancer?
Kwapisz D
Ann Transl Med; 2017 Feb; 5(3):46. PubMed ID: 28251125
[TBL] [Abstract][Full Text] [Related]
34.
Garzón M; Villatoro S; Teixidó C; Mayo C; Martínez A; de Los Llanos Gil M; Viteri S; Morales-Espinosa D; Rosell R
Transl Lung Cancer Res; 2016 Oct; 5(5):511-516. PubMed ID: 27826532
[TBL] [Abstract][Full Text] [Related]
35. Circulating Cell-Free DNA and Circulating Tumor Cells as Prognostic and Predictive Biomarkers in Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Chemotherapy.
Coco S; Alama A; Vanni I; Fontana V; Genova C; Dal Bello MG; Truini A; Rijavec E; Biello F; Sini C; Burrafato G; Maggioni C; Barletta G; Grossi F
Int J Mol Sci; 2017 May; 18(5):. PubMed ID: 28492516
[TBL] [Abstract][Full Text] [Related]
36. Biopsy-free circulating tumor DNA assay identifies actionable mutations in lung cancer.
Villaflor V; Won B; Nagy R; Banks K; Lanman RB; Talasaz A; Salgia R
Oncotarget; 2016 Oct; 7(41):66880-66891. PubMed ID: 27602770
[TBL] [Abstract][Full Text] [Related]
37. Role of liquid biopsy in oncogene-addicted non-small cell lung cancer.
Canale M; Pasini L; Bronte G; Delmonte A; Cravero P; Crinò L; Ulivi P
Transl Lung Cancer Res; 2019 Nov; 8(Suppl 3):S265-S279. PubMed ID: 31857950
[TBL] [Abstract][Full Text] [Related]
38. A field guide for cancer diagnostics using cell-free DNA: From principles to practice and clinical applications.
Volckmar AL; Sültmann H; Riediger A; Fioretos T; Schirmacher P; Endris V; Stenzinger A; Dietz S
Genes Chromosomes Cancer; 2018 Mar; 57(3):123-139. PubMed ID: 29205637
[TBL] [Abstract][Full Text] [Related]
39. [Influence of Different Therapies on EGFR Mutants by Circulating Cell-free DNA of Lung Adenocarcinoma and Prognosis].
Su F; Zheng K; Fu Y; Wu Q; Tang Y; Wang W; Jiang L
Zhongguo Fei Ai Za Zhi; 2018 May; 21(5):389-396. PubMed ID: 29764589
[TBL] [Abstract][Full Text] [Related]
40. Blood-based tumor biomarkers in lung cancer for detection and treatment.
Mamdani H; Ahmed S; Armstrong S; Mok T; Jalal SI
Transl Lung Cancer Res; 2017 Dec; 6(6):648-660. PubMed ID: 29218268
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
